How Alexion Pharmaceuticals Knocked It Out of the Park in Q1
Alexion Pharmaceuticals released better-than-expected first-quarter financial results before the markets opened on Thursday.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 137
Major Biotechs Face Rising Tide of Short Interest
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Short Sellers Grow More Selective on Major Pharma Stocks
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Why Eli Lilly’s Big Earnings Beat, Rosy Guidance Were Not Enough
Eli Lilly released its most recent quarterly earnings report before the markets opened on Tuesday.
Unity Biotech Announces Potential Pricing for IPO
Unity Biotechnology plans to offer 5 million shares in an initial public offering valued up to more than $103 million.
Can Epizyme Survive This FDA Hold?
Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the firm's tazemetostat trials.
Why Some Investors May Still Look at Prothena, But With Very Different Views
Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease…
Can Akorn Win Its Fight Against Fresenius?
Fresenius said Sunday it would terminate its offer to acquire Akorn as the result of the latter's "failure to fulfill several closing conditions."
Why Prothena Is Crashing
Prothena shares hit a multiyear low on Monday, one that had not been seen since 2013, on the heels of news that the company would be discontinuing development of its treatment for AL amyloidosis.
Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Will the FDA Shoot Down Eli Lilly and Incyte Again?
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
What to Expect From the Newest Biogen Collaboration
Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.
Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA
GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday.
Aceto Has a Heart Attack
There is a lot going on for Aceto in its latest update, and most of it is not good news. Amid credit negotiations, there are also changes at the highest level of management, making…
The FDA Strikes Again at Calithera Biosciences
Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.